Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma

BMC Cancer

Volumn 4, Issue , 2004, Pages

  Lewis, Michael J ^a   Wiebe, John P ^a   Heathcote, J Godfrey ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

20ALPHA HYDROXYSTEROID DEHYDROGENASE; 3ALPHA HYDROXYSTEROID DEHYDROGENASE; 5ALPHA PREGNANE 3,20 DIONE; MESSENGER RNA; RNA 18S; STEROID 5ALPHA REDUCTASE; 15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3 ALPHA BETA, 20 BETA HYDROXYSTEROID DEHYDROGENASE; 3 ALPHA-BETA, 20 BETA-HYDROXYSTEROID DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; 3ALPHA(OR 20BETA) HYDROXYSTEROID DEHYDROGENASE; AKR1C2 PROTEIN, HUMAN; AKR1C3 PROTEIN, HUMAN; HYDROXYSTEROID DEHYDROGENASE; PROGESTERONE;

ADULT; AGED; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST REDUCTION; CANCER CELL CULTURE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; METASTASIS; MITOGENESIS; PROGESTERONE METABOLISM; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; BREAST TUMOR; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE;

20-HYDROXYSTEROID DEHYDROGENASES; 3-HYDROXYSTEROID DEHYDROGENASES; 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; HYDROXYSTEROID DEHYDROGENASES; MIDDLE AGED; PROGESTERONE; RNA, MESSENGER;

EID: 5644274754     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-4-27     Document Type: Article

References (39)

1. Mori M, Tamaoki BI: Formation of a steroidal allyl alcohol in the mammary glands of mice. Steroids 1977, 29:517-524.
2. Mori M, Tamaoki BI: In vitro metabolism of progesterone in the mammary tumor and the normal mammary gland of GRS/A strain of mice and dependency of some steroid- metabolizing enzyme activities upon ovarian function. European Journal of Cancer 1980, 16: 85-193.
3. Mori M, Tominaga T, Tamaoki BI: Steroid metabolism in normal mammary gland and in the dimethylbenzanthracene-induced mammary tumor of rats. Endocrinology 1978, 102:1387-1397.
4. Mori M, Tominaga T, Kitamura M, Saito T, Tamaoki B: Effect of oophorectomy on progesterone metabolism in DMBA-induced mammary tumours of the rat. European Journal of Cancer 1980, 16: 373-1375.
5. Eechaute W, de Thibault de Boesinghe L, Lacroix E: Steroid metabolism and steroid receptors in dimethylbenz(a)anthracene-induced rat mammary tumors. 1983, 43: 4260-4265. Cancer Research 1983, 43:4260-4265.
6. Shiota K, Sasaki N, Hattori N, Miura R, Hasegawa T, Guang JX, Noda K, Takahashi M: Cytosolic 20α-hydroxysteroid dehydrogenase activity in spontaneous neoplasms in the dog and cat. Journal of Veterinary Medical Science 1991, 53:549-552.
7. Tanaka NM, Shiota K, Noda K, Kokubo S, Kadosawa T, Nishimura R, Takahashi M, Sasaki N: 20Hydroxysteroid dehydrogenase activity in canine spontaneous neoplasms. Journal of Veterinary Medical Science 1994, 56:581-583.
8. Verma U, Kapur MM, Laumas KR: Characterization of progesterone receptors and metabolism of progesterone in the normal and cancerous human mammary gland. Journal of Steroid Biochemistry 1978, 9:569-577.
9. Lloyd RV: Studies on the progesterone receptor content and steroid metabolism in normal and pathological human breast tissues. Journal of Clinical Endocrinology and Metabolism 1979, 48: 85-593.
10. Wiebe John P., Muzia David, Hu Juncai, Szwajcer David, Hill Scott A., Seachrist Jennifer L.: The 4-pregnene and 5α-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Research 2000, 60:936-943.
11. Wiebe John P., Muzia D: The endogenous progesterone metabolite, 5α-pregnane-3,20-dione, decreases cell-substrate attachment, adhesion plaques, vinculin expression, and polymerized F-actin in MCF-7 breast cancer cells. Endocrine 2001, 16:7-14.
12. Weiler Peter J., Wiebe John P.: Plasma membrane receptors for the cancer-regulating progesterone metabolites, 5α-pregnane-3,20-dione and 3α-hydroxy-4-pregnen-20- one in MCF-7 breast cancer cells. Biochemical and Biophysical Resarch Communications 2000, 272:731-737.
13. Wiebe John P., Lewis Michael J.: Activity and expression of progesterone metabolizing 5α-reductase, 20α-hydroxysteroid oxidoreductase and 3α (b)-hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells. BMC Cancer 2003, 3:1-15.
14. Ji Q, Chang L, VanDen Berg D, Stanczyk FZ, Stolz A: Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism. Prostate 2003, 54:275-289.
15. Horwitz KB, Pike AW, Gonzales-Aller C, Fennessey PV: Progesterone metabolism in T47Dco human breast cancer cells - II. Intracellular metabolic path of progesterone and synthetic progestins. Journal of Steroid Biochemistry 1986, 25:911-916.
16. Andersson S, Russell DW: Structural and biochemical properties of cloned and expressed human and rat steroid 5α -reductases. Proceedings of the National Academy of Sciences USA 1990, 87: 640-3644.
17. Russell DW, Wilson JD: Steroid 5α-reductase: two genes/two enzymes. Annual Review of Biochemistry 1994, 63: 5-61.
18. Russell DW, Berman DM, Bryant JT, Cala KM, Davis DL, Landrum CP, Prihoda JS, Silver RI, Thigpen AE, Wigley WC: The molecular genetics of steroid 5α-reductases. Recent Progress in Hormone Research 1994, 49:275-284.
19. Thigpen AE, Silver RI, Guileyardo JM, Casey M,L,, McConnell JD, Russell DW: Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. Journla of Clinical Investigations 1993, 92:903-910.
20. Suzuki T, Darnel AD, Akahira JI, Ariga N, Ogawa S, Kaneko C, Takeyama J, Moriya T, Sasano H: 5α-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. Journal of Clinical Endocrinology and Metabolism 2001, 86: 250-2257.
21. Jin Y, Penning TM: Steroid 5α-reductases and 3α-hydroxysteroid dehydrogenases: key enzymes in androgen metabolism. Best Practice Research Clinical Endocrinology and Metabolism 2001, 15:79-94.
22. Dufort I, Soucy P, Labrie F, Luu-The V: Molecular cloning of human type 3 3α-hydroxysteroid dehydrogenase that differs from 20α-hydroxysteroid dehydrogenase by seven amino acids. Biochemical and Biophysical Resarch Communications 1996, 228:474-479.
23. Dufort I, Rheault P, Huang XF, Soucy P, Luu-The V: Characteristics of a highly labile human type 5 17β -hydroxysteroid dehydrogenase. Endocrinology 1999, 140:568-574.
24. Dufort I, Labrie F, Luu-The V: Human types 1 and 3 3α-hydroxysteroid dehydrogenases: differential lability and tissue distribution. Journal of Clinical Endocrinology and Metabolism 2001, 86:841-846.
25. Stolz A, Hammond L, Lou H, Takikawa H, Ronk M, Shively JE: cDNA cloning and expression of the human hepatic bile acid-binding protein. A member of the monomeric reductase gene family. Journal of Biological Chemistry 1993, 268:10448-10457.
26. Penning TM: Molecular endocrinology of hydroxysteroid dehydrogenases. Endocrine Reviews 1997, 18:281-305.
27. Khanna M, Qin KN, Wang RW, Cheng KC: Substrate specificity, gene structure, and tissue-specific distribution of multiple human 3α-hydroxysteroid dehydrogenases. Journal of Biological Chemistry 1995, 270:20162-20168.
28. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N, Ratnam K: Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1 - AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochemical Journal 2000, 351:67-77.
29. Zhang Y, Dufort I, Rheault P, Luu-The V: Characterization of a human 20α-hydroxysteroid dehydrogenase. Journal of Molecular Endocrinology 2000, 25:221-228.
30. Ji Q, Aoyama C, Nien Y-D, Chen P, Liu P, Stolz A: Reduced expression of human 20α-hydroxysteroid dehydrogenase (20α -HSD) in human breast cancer cases [abstract]. Endocrine Society Annual Meeting Abstracts 2003, 2003:P2,443.
31. Hardy DO, Ge RS, Catterall JF, Hou YT, Penning TM, Hardy MP: Identification of the oxidative 3α-hydroxysteroid dehydrogenase activity of rat Leydig cells as type II retinol dehydrogenase. Endocrinology 2000, 141:1608-1617.
32. Campbell SMC, Wiebe JP: Stimulation of spermatocyte development in prepubertal rats by the Sertoli cell steroid, 3α-hydroxy-4-pregnen-20-one. Biology of Reproduction 1989, 40:897-905.
33. Wood PH, Wiebe JP: Selective suppression of follicle-stimulating hormone secretion in anterior pituitary cells by the gonadal steroid, 3α-hydroxy-4-pregnen-20-one (3αHP). Endocrinology 1989, 125:41-48.
34. Dhanvantari S, Wiebe JP: Suppression of follicle-stimulating hormone by the gonadal- and neurosteroid 3α-hydroxy-4-pregnen-20-one involves actions at the level of the gonadotrope membrane/calcium channel. Endocrinology 1994, 134:371-376.
35. Wiebe JP, Dhanvantari Savita, Watson PH, Huang Y: Suppression in gonadotropes of gonadotropin-releasing hormone-stimulated follicle-stimulating hormone release by the gonadaland neurosteroid 3α-hydroxy-4-pregnen-20-one involves cytosolic calcium. Endocrinology 1994, 134:377-382.
36. Beck Christine A., Wolfe M, Murphy LD, Wiebe JP: Acute, nongenomic actions of the neuroactive gonadal steroid, 3α-hydroxy-4-pregnen-20-one (3αHP), on FSH release in perifused rat anterior pituitary cells. Endocrine 1997, 6:221-229.
37. Wiebe JP: Nongenomic actions of steroids on gonadotropin release. Recent Progress in Hormone Research 1997, 52: 1-101.
38. Wiebe John P., Kavaliers Martin: Analgesic effects of the putative FSH-suppressing gonadal steroid, 3α -hydroxy-4-pregnen-20-one: possible modes of action. Brain Research 1988, 461: 50-157.
39. Kavaliers Martin, Wiebe John P., Galea LAM: Reduction of predator-induced anxiety in mice by the neurosteroid 3α-hydroxy-4-pregnen-20-one (3αHP). Brain Research 1994, 645:325-329.